Bronchiectasis

Leigh Minuk, MD FRCPC

General Internal Medicine Noon Rounds

August 18, 2025

Learning Objectives

1. Understand the proposed mechanism of airway inflammation in bronchiectasis.
2. Propose likely scenarios when bronchiectasis should be considered on the differential diagnosis.
3. Describe the differential diagnosis of bronchiectasis and initial tests in the workup of bronchiectasis.
4. List management principles in exacerbation and treatment goals.

Question 1

- In which clinical scenario(s) might you suspect a diagnosis of bronchiectasis:
  A. 28-year-old woman with atopy, dry cough and positive methacholine challenge test.
  B. 84-year-old woman, lifelong non-smoker, with recurrent aspiration pneumonia and chronic productive cough with sputum cultures positive for P. aeruginosa.
  C. 67-year-old man, former heavy smoker, with COPD and two exacerbations with sputum culture positive for S. pneumo.
  D. 72-year-old woman with longstanding rheumatoid arthritis well-controlled on methotrexate and plaquenil and new exertional dyspnea.

Pathophysiology of Bronchiectasis



Chronic Infection

Impaired Mucociliary Clearance

Structural Lung Disease

Inflammation

O'Donnell et al., NEJM, 2022.

Clinical Presentation of Bronchiectasis

- Characterized by respiratory symptoms
  - Chronic cough
  - Mucopurulent sputum production
  - Recurrent chest infections
  - Hemoptysis
- Consider investigating patients with:
  - COPD and ≥ 2 exacerbations and previous sputum culture positive for pseudomonas while stable.
  - Asthma and severe or poorly controlled disease
  - History of chronic productive cough or frequent respiratory infection in HIV infection, immunosuppressive therapy, connective tissue disease, inflammatory bowel disease

.
Hill et al., BTS, 2018.

Question 1

- In which clinical scenario(s) might you suspect a diagnosis of bronchiectasis:
  A. 28-year-old woman with atopy, dry cough and positive methacholine challenge test.
  B. 84-year-old woman, lifelong non-smoker, with recurrent aspiration pneumonia and chronic productive cough with sputum cultures positive for P. aeruginosa.
  C. 67-year-old man, former heavy smoker, with COPD and two exacerbations with sputum culture positive for S. pneumo.
  D. 72-year-old woman with longstanding rheumatoid arthritis well-controlled on methotrexate and plaquenil and new exertional dyspnea.

Radiological features of Bronchiectasis

Question 2

- What imaging features would lead you to suspect a diagnosis of bronchiectasis?
  A. Consolidation on chest x-ray.
  B. Reticulation on chest x-ray.
  C. Lack of airway tapering on CT chest.
  D. Cystic ring sign on CT chest.
  E. Tree-in-bud nodules on CT chest.

Radiological features of bronchiectasis







CT Features:

1. Lack of airway tapering (B)
2. Signet ring sign (C)
3. Airway visible within 1 cm of pleura
4. Mucous plugging (D)

Cantin et al, AJR, 2012
McShane et al, ARJCCM, 2013

Radiological features of bronchiectasis



Cantin et. al, AJR, 2012

Question 2

- What imaging features would lead you to suspect a diagnosis of bronchiectasis?
  A. Consolidation on chest x-ray.
  B. Reticulation on chest x-ray.
  C. Lack of airway tapering on CT chest.
  D. Cystic ring sign on CT chest.
  E. Tree-in-bud nodules on CT chest.

Diagnostic Workup

Question 3 (scenario)

A 37-year-old man, lifelong non-smoker, presents with chronic cough productive of yellow sputum for many years. He recently had another episode of “pneumonia” where his sputum turned green and he required inpatient admission. He has a history of nasal congestion, sinusitis and otitis media which started in childhood, requiring tympanostomy tubes. Immunoglobulins done in childhood were normal. He and his wife (she has a child from a previous marriage) have been unable to conceive.

Which test if positive would help support your suspected diagnosis:

A. Positive sweat chloride test.
B. Positive nasal nitric oxide test.
C. Positive alpha-1-antitrypsin.
D. Total IgE >12,000.

Causes of Bronchiectasis

Focal

- Foreign body
- Bronchial stenosis
- Airway stenosis
- Bronchial atresia

Bronchoscopy is often the first step to rule out endobronchial lesion or foreign body

Diffuse

- Idiopathic
- Postinfectious
- Aspiration
- Immunodeficiency
- Autoimmune
- Mycobacterial disease
- Cystic fibrosis
- Primary ciliary dyskinesia
- Allergic bronchopulmonary aspergillosis
- Rare: Yellow Nail Syndrome, Mounier Kuhn, William's Campbell Syndrome.

Cantin et. al, AJR, 2012

Initial workup and evaluation of bronchiectasis

CT Chest (Most are diffuse)

- Lower lobe: aspiration, recurrent infection, fibrosis-related.
- Central: ABPA.
- Upper lobe: Cystic Fibrosis, post radiation, sarcoidosis.

PFT

- **Spirometry**
  Normal (59%)
  Obstruction: FEV1/FVC ≤ LLN (41%)
- **Plethysmography**
  Air trapping: RV/TLC ≤ LLN (70%)
  Restriction: TLC ≤ LLN (8%)
- Reduced DLCO: ≤75% (56%)

Labs

- CBC, IgE and aspergillus specific IgE. IgG, IgM, IgA, pneumococcal polysaccharide antibodies.
- Sputum culture for bacterial and NTM.
- HIV, RF, CCP, ANCA, ANA, A1AT, CF, PCD if other clinical features.

Further testing should be guided by specific clinical scenario and patient factors

Radovanovic et al., Respiratory Medicine, 2018.
Hill et al., BTS, 2018.

Why these tests?

CBC
IgE and aspergillus specific IgE

IgG, IgM, IgA

Allergic Bronchopulmonary Aspergillosis

Immunodeficiency

Potential Treatment Targets: Corticosteroids and antifungals, IVIG

Hill et al., BTS, 2018.

History directed at cause

- History of tuberculosis/non-tuberculous mycobacterial infection, or severe respiratory infection.
- Neonatal/early childhood respiratory infection.
- Recurrent aspiration.
- Symptoms of recurrent infection.
- Autoimmune history: known or suspected rheumatoid arthritis, Sjogren's (e.g., inflammatory arthritis, sicca symptoms).
- Atopic symptoms.
- Chronic nasal congestion and rhinorrhea, recurrent otitis media, reduced fertility in men or women.
- Early onset, male infertility, malabsorption, pancreatitis.

The majority of cases are idiopathic or postinfectious

Hill et al., BTS, 2018.

Testing directed at cause

Clinical Features	Suspected Diagnosis	Test

Smith et al, CMAJ, 2017

Question 3 (scenario)

A 37-year-old man, lifelong non-smoker, presents with chronic cough productive of yellow sputum for many years. He recently had another episode of “pneumonia” where his sputum turned green and he required inpatient admission. He has a history of nasal congestion, sinusitis and otitis media which started in childhood, requiring tympanostomy tubes. Immunoglobulins done in childhood were normal. He and his wife (she has a child from a previous marriage) have been unable to conceive.

Which test if positive would help support your suspected diagnosis:

A. Positive sweat chloride test.
B. Positive nasal nitric oxide test.
C. Positive alpha-1-antitrypsin.
D. Total IgE >12,000.

Pseudomonas colonization

Finch et al. Annals ATS, 2015



Study or Subgroup	Pseudomonas Events	Pseudomonas Total	Non-Pseudomonas Events	Non-Pseudomonas Total	Weight	Odds Ratio M-H, Random, 95% CI
Aliberti 2014	3	39	0	162	1.7%	31.16 [1.58, 616.55]
Chalmers 2014	15	70	47	538	17.9%	2.85 [1.50, 5.43]
Chalmers 2015	6	44	17	242	11.0%	2.09 [0.77, 5.64]
Goeminne 2014	10	20	20	225	11.0%	10.25 [3.81, 27.57]
Loebinger 2009	8	20	19	71	10.3%	1.82 [0.65, 5.15]
Martinez-Garcia 2014	38	126	41	271	21.8%	2.42 [1.46, 4.01]
McDonnell 2014	9	47	13	108	12.0%	1.73 [0.68, 4.38]
McDonnell 2015	13	34	27	178	14.3%	3.46 [1.55, 7.73]
Total (95% CI)		400		1795	100.0%	2.95 [1.98, 4.40]
Total events	102		184			

Heterogeneity: $Tau^2 = 0.13$; $Chi^2 = 11.72$, df = 7 (P = 0.11); $I^2 = 40\%$
Test for overall effect: Z = 5.29 (P < 0.00001)

Odds Ratio M-H, Random, 95% CI
0.05 0.2 1 5 20



Study or Subgroup	Pseudomonas Events	Pseudomonas Total	Non-Pseudomonas Events	Non-Pseudomonas Total	Weight	Odds Ratio M-H, Random, 95% CI
Aliberti 2014	16	39	25	162	15.0%	3.81 [1.77, 8.21]
Chalmers 2014	62	70	127	538	15.1%	25.08 [11.70, 53.78]
Chalmers 2015	33	44	69	242	15.2%	7.52 [3.60, 15.72]
Kelly 2003	13	21	10	56	12.7%	7.47 [2.45, 22.80]
King 2007	7	27	6	62	12.1%	3.27 [0.98, 10.89]
McDonnell 2014	21	47	32	108	15.4%	1.92 [0.94, 3.89]
McDonnell 2015	24	34	25	178	14.5%	14.69 [6.28, 34.37]
Total (95% CI)		282		1346	100.0%	6.57 [3.19, 13.51]
Total events	176		294			

Heterogeneity: $Tau^2 = 0.75$; $Chi^2 = 30.50$, df = 6 (P < 0.0001); $I^2 = 80\%$
Test for overall effect: Z = 5.11 (P < 0.00001)

Odds Ratio M-H, Random, 95% CI
0.02 0.1 1 10 50



Study or Subgroup	Pseudomonas Mean	Pseudomonas SD	Pseudomonas Total	Non-Pseudomonas Mean	Non-Pseudomonas SD	Non-Pseudomonas Total	Weight	Mean Difference IV, Random, 95% CI
Aliberti 2014	2.74	1.98	39	1.55	2.1	162	12.2%	1.19 [0.49, 1.89]
Chalmers 2014	2.85	1.5	70	1.8	1.4	538	20.4%	1.05 [0.68, 1.42]
Chalmers 2015	2.4	1.4	44	1.9	1.4	242	18.2%	0.50 [0.05, 0.95]
Kelly 2003	5.52	3.47	21	4.57	3.57	56	3.1%	0.95 [–0.80, 2.70]
King 2007	4.1	1.7	27	3.5	1.8	43	9.9%	0.60 [–0.24, 1.44]
McDonnell 2014	4.6	2.6	47	4.3	3.3	108	8.1%	0.30 [–0.67, 1.27]
McDonnell 2015	3.9	1.2	34	2.9	0.9	178	18.9%	1.00 [0.58, 1.42]
Rogers 2014	6.1	3	26	3.5	1.4	34	5.6%	2.60 [1.35, 3.85]
Tsang 2000	4.1	3.46	22	2.1	1.02	8	3.6%	2.00 [0.39, 3.61]
Total (95% CI)			330			1369	100.0%	0.97 [0.64, 1.30]

Heterogeneity: $Tau^2 = 0.10$; $Chi^2 = 15.37$, df = 8 (P = 0.05); $I^2 = 48\%$
Test for overall effect: Z = 5.78 (P < 0.00001)

Mean Difference IV, Random, 95% CI
–4 –2 0 2 4
Pseudomonas protective
Pseudomonas harmful

Increased Risk of Mortality

Increased Risk of Hospital Admission

Increased Exacerbation Frequency

Infectious Etiologies in Non-CF and CF Bronchiectasis Exacerbations

Non CF Bronchiectasis

1. *Haemophilus influenza*
2. *Streptoccocus pneumonia*
3. *Pseudomonas aeruginosa*

- *Staphylococcus aureus* and *Moraxella catarrhalis*

CF Bronchiectasis

1. *Pseudomonas aeruginosa*
2. *Staphylococcus aureus*
3. *Haemophilus influenza*

- *Steptoccocus pneumonia* and *Moraxella catarrhalis*

Non-Tuberculous Mycobacterium

≥ 2 Sputum Cultures

Isolation on bronchoscopy

Isolation on biopsy

Griffiths et al, ARJCCM, 2020

Management of Bronchiectasis

General Management Targets

Chronic bronchial infection
Long-term inhaled or oral antibiotic therapy
Eradication of new pathogenic microorganisms
Antibiotic treatment of exacerbations

Structural lung disease
Long-term bronchodilator therapy
Surgery
Pulmonary rehabilitation



Inflammation
Long-term anti-inflammatory therapies

Impaired mucociliary clearance
Long-term mucoactive treatments
Airway clearance

Polverino et al., ERJ, 2017

Management Overview



Adapted from Polverino et al., ERJ, 2017

Airway Clearance:
Active Cycle of Breathing Techniques



Airway Clearance: Devices

- PEP Devices
- Oscillating PEP Devices
- High frequency chest wall oscillation devices

Mucolytics and Bronchodilators

- Bronchodilators
  - Can improve symptoms.
  - LAMA and LABA or SABA/SAMA.
- Mucolytics
  - **If difficulty expectorating sputum and poor quality of life and standard airway clearance techniques have failed to control symptoms**
  - **<u>Do not reduce exacerbations</u>**
    - Hypertonic saline or mannitol
    - DNAse contraindicated

Hill et al, BTS, 2018.
O'Donnell et al, Chest, 1998.

Inhaled corticosteroids are not recommended



Increased risk of pneumonia and risk of NTM pulmonary disease

Reasonable to use ICS in Asthma

and

Low-dose ICS for preventing COPD exacerbations

Brode et al. ERJ 2017

Long-Term Antimicrobial Therapy



Tobramycin
Gentamicin
Colistin

Consider switching if ineffective

Polverino et al., ERJ, 2017

Surgery and Lung Transplant

When to consider surgery:

- Localized disease.
- Persistent symptoms despite a year of comprehensive medical management.
- Severe/Frequent exacerbations.
- Localized severely damaged lobe or segment that may be a source of sepsis that left in situ may lead to exacerbation of lung damage.

- When to consider lung transplant:
  - Age <65 (cutoff 70 years in BC).
  - FEV1 <30% with frequent exacerbations.



Gaillard F, Glick Y, Bickle I, et al. Middle lobe bronchiectasis. Radiopaedia.org

Hill et al., BTS, 2018.

Bronchiectasis Exacerbation Management

- Sputum cultures
- Empiric antibiotics
  - Targeted antimicrobials recommended, but no effect on outcome
- Recommended 14-day course of antimicrobials
- Inhaled tranexamic acid in hemoptysis
- If massive hemoptysis, early evaluation for embolization

Hill et al., BTS, 2018.

Questions?